Insider Selling: Merck & Co., Inc. (MRK) CEO Sells 92,913 Shares of Stock

Merck & Co., Inc. (NYSE:MRK) CEO Kenneth C. Frazier sold 92,913 shares of the business’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $80.03, for a total transaction of $7,435,827.39. Following the sale, the chief executive officer now directly owns 784,863 shares in the company, valued at $62,812,585.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

NYSE:MRK traded down $0.57 during mid-day trading on Tuesday, hitting $79.24. The company’s stock had a trading volume of 9,210,257 shares, compared to its average volume of 12,753,371. Merck & Co., Inc. has a 1 year low of $52.83 and a 1 year high of $80.19. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.15 and a current ratio of 1.44. The firm has a market cap of $215.18 billion, a price-to-earnings ratio of 18.26, a PEG ratio of 2.09 and a beta of 0.62.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Friday, February 1st. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.03 by $0.01. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 35.10%. The company had revenue of $11 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the prior year, the company earned $0.98 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. As a group, equities research analysts predict that Merck & Co., Inc. will post 4.66 earnings per share for the current fiscal year.



Merck & Co., Inc. announced that its board has approved a stock repurchase plan on Thursday, October 25th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 5.1% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 2.78%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s payout ratio is 50.69%.

A number of equities research analysts have recently weighed in on MRK shares. SunTrust Banks boosted their price objective on shares of Merck & Co., Inc. from $77.00 to $80.00 and gave the company a “buy” rating in a report on Monday, October 29th. Citigroup boosted their price objective on shares of Merck & Co., Inc. from $79.00 to $84.00 and gave the company a “buy” rating in a report on Wednesday, October 31st. Zacks Investment Research lowered shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 24th. Morgan Stanley set a $81.00 price objective on shares of Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, December 20th. Finally, BMO Capital Markets lowered shares of Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price objective on the stock. in a report on Wednesday, January 23rd. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $73.80.

Large investors have recently bought and sold shares of the business. PRW Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $41,000. Contravisory Investment Management Inc. raised its position in shares of Merck & Co., Inc. by 186.4% in the fourth quarter. Contravisory Investment Management Inc. now owns 653 shares of the company’s stock worth $50,000 after acquiring an additional 425 shares during the period. Arlington Partners LLC raised its position in shares of Merck & Co., Inc. by 93.5% in the fourth quarter. Arlington Partners LLC now owns 828 shares of the company’s stock worth $63,000 after acquiring an additional 400 shares during the period. Advisors Preferred LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $66,000. Finally, Financial Gravity Companies Inc. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $66,000. 74.29% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://dakotafinancialnews.com/2019/02/20/insider-selling-merck-co-inc-mrk-ceo-sells-92913-shares-of-stock.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Story: How is an ETF different from a mutual fund?

Insider Buying and Selling by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.